Dr. Chanda Macias
Executive DirectorWomen GrowDr. Chanda Macias is a global healthcare and cannabis industry leader with 25+ years of experience across cannabis, healthcare, education, and regulated consumer products. She specializes in building and managing compliant, end-to-end supply chains in highly regulated environments—integrating operations, quality, and regulatory frameworks across multiple jurisdictions.
Dr. Macias is the CEO of National Holistic Healthcare, a U.S.-based medical cannabis cultivator, processor, and dispensary organization. Her cannabis journey began with the flagship National Holistic™ Healing Center in Washington, D.C., where she helped build one of the region’s leading dispensaries—centered on patient care, education, and holistic self-care.
Borders Without Barriers: Building Global Cannabis Clinical Trials That Scale
Cannabis research no longer stops at national lines. As medical programs mature across the US, Canada, the UK, and beyond, international clinical tri
Cannabis research no longer stops at national lines. As medical programs mature across the US, Canada, the UK, and beyond, international clinical trial collaboration has become the fastest route to credible data, regulatory approval, and commercial
Cannabis research no longer stops at national lines. As medical programs mature across the US, Canada, the UK, and beyond, international clinical trial collaboration has become the fastest route to credible data, regulatory approval, and commercial scale. Yet most operators still struggle with mismatched standards, fragmented data-sharing rules, and approval timelines that differ by jurisdiction.
This session maps the current global trial lan
Cannabis research no longer stops at national lines. As medical programs mature across the US, Canada, the UK, and beyond, international clinical trial collaboration has become the fastest route to credible data, regulatory approval, and commercial scale. Yet most operators still struggle with mismatched standards, fragmented data-sharing rules, and approval timelines that differ by jurisdiction.
This session maps the current global trial landscape and the real obstacles to cross-border partnership: harmonizing pharmaceutical standards, navigating conflicting regulations, and protecting data integrity across regions. You'll see how shared evidence accelerates product development and unlocks new cannabis industry opportunities in markets that demand clinical proof.
Drawing on current cannabis market trends, our experts connect research strategy to commercial reality, showing how global collaboration shortens the path from study to shelf. Built for pharmaceutical executives, researchers, and senior operators, this is a strategy-focused discussion with practical, real-world frameworks.
